MAP2K7 and breast carcinoma: Phorbol ester (PMA), a tumor promoter, hyper-activates the MEK/Erk1/2 pathway and increases phosphorylation of S6K/S6 in SKBR3 breast cancer cells, which can be abrogated by co-treatment with U0126 and rapamycin [54].